Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M223,437Revenue (TTM) $M52,759Net Margin (%)17.6Altman Z-Score3.6
Enterprise Value $M232,024EPS (TTM) $1.4Operating Margin %27.4Piotroski F-Score5
P/E(ttm)24.4Beneish M-Score-2.9Pre-tax Margin (%)23.8Higher ROA y-yN
Price/Book10.210-y EBITDA Growth Rate %3.1Quick Ratio0.9Cash flow > EarningsY
Price/Sales4.35-y EBITDA Growth Rate %1.5Current Ratio1.2Lower Leverage y-yY
Price/Free Cash Flow19.4y-y EBITDA Growth Rate %-6.1ROA % (ttm)12.1Higher Current Ratio y-yN
Dividend Yield %3.2PEG16.3ROE % (ttm)46.1Less Shares Outstanding y-yY
Payout Ratio %77.0Shares Outstanding M6,818ROIC % (ttm)30.4Gross Margin Increase y-yN

Gurus Latest Trades with RHHBY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
RHHBYKen Fisher 2016-03-31 Add0.02%$30.09 - $34.47
($31.91)
$ 31.52-1%Add 1.88%14,906,191
RHHBYKen Fisher 2015-12-31 Add0.01%$32.55 - $35.08
($33.69)
$ 31.52-6%Add 0.63%14,630,453
RHHBYKen Fisher 2015-09-30 Add0.02%$31.65 - $36.87
($34.69)
$ 31.52-9%Add 2.30%14,538,602
RHHBYKen Fisher 2015-06-30 Add0.8%$34.38 - $38.46
($36.09)
$ 31.52-13%Add 409.71%14,211,412
RHHBYKen Fisher 2015-03-31 Reduce$32.1 - $36.505
($34.06)
$ 31.52-7%Reduce -1.24%2,788,126
RHHBYKen Fisher 2014-12-31 Add0.07%$34.16 - $37.92
($36.33)
$ 31.52-13%Add 49.26%2,823,025
RHHBYKen Fisher 2014-06-30 Reduce-0.07%$35.42 - $38.07
($36.82)
$ 31.52-14%Reduce -49.71%1,813,443
RHHBYKen Fisher 2014-03-31 Add0.07%$18.14 - $38.17
($29.75)
$ 31.526%Add 99.00%3,606,140
RHHBYKen Fisher 2013-12-31 Reduce$31.96 - $35.24
($34.16)
$ 31.52-8%Reduce -0.26%1,812,112
RHHBYKen Fisher 2013-09-30 Add$30.66 - $33.77
($31.84)
$ 31.52-1%Add 0.28%1,816,868
RHHBYKen Fisher 2013-06-30 Add$28.92 - $32.98
($30.95)
$ 31.522%Add 0.90%1,811,804
RHHBYTweedy Browne 2013-06-30 Sold Out $28.92 - $32.98
($30.95)
$ 31.522%Sold Out0
RHHBYKen Fisher 2013-03-31 Add0.12%$25.25 - $29.3
($27.75)
$ 31.5214%Add 634.57%1,795,722
RHHBYTweedy Browne 2012-12-31 Reduce$23.08 - $25.68
($24.53)
$ 31.5228%Reduce -3.04%120,548
RHHBYKen Fisher 2012-12-31 Reduce$23.08 - $25.68
($24.53)
$ 31.5228%Reduce -14.81%244,460
RHHBYTweedy Browne 2012-09-30 Reduce-0.03%$20.99 - $24.07
($22.49)
$ 31.5240%Reduce -24.31%124,328
RHHBYKen Fisher 2012-09-30 Reduce$20.99 - $24.07
($22.49)
$ 31.5240%Reduce -7.27%286,946
RHHBYVanguard Health Care Fund 2012-06-30 Add2.96%$19.43 - $23.14
($21.16)
$ 31.5249%Add 543.36%8,547,954
RHHBYKen Fisher 2012-06-30 Reduce-0.01%$19.43 - $23.14
($21.16)
$ 31.5249%Reduce -24.26%309,426
RHHBYKen Fisher 2012-03-31 Reduce-1.27%$20.89 - $22.5
($21.77)
$ 31.5245%Reduce -98.02%408,552
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

RHHBY is held by these investors:


News about RHHBY:

Articles On GuruFocus.com
Siegfried Holdings, Held by Tweedy Browne, Way Undervalued Jul 22 2016 
Roche Holdings Definitely Not a Lumbering Giant Jul 11 2016 
Invesco Adds to Holdings in Investment, Financial Services Companies Jul 01 2016 
Bearish Sentiment in Becton Dickinson's Stock Apr 27 2016 
Does Biotech’s Recent Bounce Have Legs? Apr 22 2016 
Invesco European Growth Fund Adds to More Than 40 Existing Stakes Apr 04 2016 
Invesco European Growth Fund Adds to 7 Stakes Jan 26 2016 
Ken Fisher Cuts His Stake in Royal Bank, Buys Roche Holding Oct 12 2015 
Signature Select Canadian Fund Second Quarter 2015 Market Commentary Sep 22 2015 
Ken Fisher's most weighted buys in Q2 2015 Jul 28 2015 

More From Other Websites
Dissecting Roche’s Performance across Its Segments Jul 22 2016
Reasons behind Roche’s Better-than-Expected 2Q16 Performance Jul 22 2016
Amgen, Allergan biosimilar found as effective as Roche cancer drug Jul 21 2016
[$$] Roche says UK faces losing lead in medical research after Brexit Jul 21 2016
Roche CEO Confident Business Will Succeed Despite Turmoil Jul 21 2016
Roche CEO Confident Business Will Succeed Despite Turmoil Jul 21 2016
[$$] Roche Sales Rise on Cancer Drugs Jul 21 2016
Roche Beats First-Half Forecasts as Cancer Drug Sales Rise Jul 21 2016
Pairing New Cancer Drugs With Older Ones Bolsters Roche Profit Jul 21 2016
What Are Roche’s Truest Growth Opportunities? Jul 19 2016
Inside Roche’s Strategy to Offset Revenue Declines Jul 19 2016
Roche's Gazyva Fails in Phase III B-cell Lymphoma Study Jul 18 2016
Gauging Growth Expectations for Roche in 2Q16 and 2016 Jul 18 2016
Roche Blood Cancer Medicine Fails to Show Major Improvement Jul 18 2016
Genentech Provides Update on Phase III Study of Gazyva® in People With Previously Untreated Diffuse... Jul 18 2016
How Much Upward Potential Does Roche Really Have? Jul 15 2016
CoaguChek® PT/ INR devices for use at the point of care and for patient self-testing remain a safe... Jul 15 2016
Amgen and Daiichi Sankyo Team Up for Biosimilars in Japan Jul 14 2016
Roche Holdings Definitely Not a Lumbering Giant Jul 11 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)